QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Résumé Extracto Full Text PDF Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Articles Ahead of Print [Order Reprint] Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Campbell, C. A Articles by Skedgel, C. D Search for Related Content PubMed PubMed Citation Articles by Campbell, C. A Articles by Skedgel, C. D

PHARMACOEPIDEMIOLOGY

Topical Corticosteroid Prescribing Patterns Following Changes in Drug Benefit Status

at time of writing, Pharmacy Student, College of Pharmacy, Dalhousie University, Nova Scotia, Canada; now, Hospital Pharmacy Resident, The Ottawa Hospital General Campus, Ottawa, Ontario, Canada

Charmaine A Cooke, BSc (Pharm)

MSc Candidate, College of Pharmacy, Dalhousie University

Swarna DS Weerasinghe, PhD

Assistant Professor, Community Health and Epidemiology, Dalhousie University

Ingrid S Sketris, PharmD MPA (HSA)

Professor, College of Pharmacy, Dalhousie University

Pam R McLean-Veysey, BSc Pharm

Drug Evaluation Pharmacist, Capital District Health Authority, Halifax

Chris D Skedgel, MDE

at time of writing, Research Analyst, Population Health Research Unit, Dalhousie University; now, Research Health Economist, Department of Medicine, Dalhousie University

Reprints: Ingrid S Sketris PharmD MPA (HSA), College of Pharmacy, Dalhousie University, 5968 College St., Halifax, Nova Scotia, Canada, B3H 3J5, FAX 902/494-1396, E-mail ingrid.sketris{at}dal.ca

OBJECTIVE: To examine changes in prescribing patterns for topical corticosteroid products dispensed to elderly patients in Nova Scotia, Canada, after all but 2 combination topical corticosteroid products were removed from the Nova Scotia Seniors' Pharmacare Program benefit list.

METHODS: Administrative prescription claims from the Nova Scotia Seniors' Pharmacare Program were used to identify the number and costs of topical corticosteroid, antifungal, antibiotic, and combination corticosteroid products dispensed. Time-series analysis was used to compare the periods before (April 1, 1999–March 31, 2000) and after (April 1, 2000–March 31, 2001) the delisting.

RESULTS: In 1999–2000, 26 031 of 103 400 eligible elderly patients (25%) and in 2000–2001, 22 837 of 95 550 eligible elderly (24%) received a prescription for a defined topical product. Nova Scotia Seniors' Pharmacare Program expenditures for all topical products decreased from $11.88 to $10.60 (CND) per beneficiary per year (11%) after the policy revision. Topical combination products decreased from 18% of all topical products dispensed to 14%, while the percentage of potent corticosteroid products dispensed increased from 24% to 27% over the study period. Pre- and post-policy time–trend analysis showed statistically significant increasing trends in cost per beneficiary for all topical products and potent corticosteroid products. Combination corticosteroid products showed no change in trends for costs per beneficiary before, and a slight increasing trend after, the policy revision.

CONCLUSIONS: Prescribing of topical corticosteroid combination products in Nova Scotia decreased following the formulary revision. There was an increase in potent topical corticosteroid prescribing. Future study involving evaluation of patient outcomes would be useful.

Key Words: elderly, formulary, topical corticosteroids

This article has been cited by other articles:

				D. P. Goldman, G. F. Joyce, and Y. Zheng Prescription Drug Cost Sharing: Associations With Medication and Medical Utilization and Spending and Health JAMA, July 4, 2007; 298(1): 61 - 69. [Abstract] [Full Text] [PDF]